Size | Price | |
---|---|---|
100mg | ||
250mg | ||
500mg |
ln Vitro |
GDC-046 exhibited a moderate level of potency in IL-12 pathway blocking (IL-12 pSTAT4 EC50=380 nM) in assays involving cells; however, it was less effective in IL and blocked the EPO (JAK2) pathway (EPO pSTAT5 EC50=1700 nM). -6 (JAK1) pathway (EC50=2000 nM for IL-6 pSTAT3)[1].
|
---|---|
ln Vivo |
In mice, GDC-046 displayed relatively high clearance (65 mL/min/kg) when injected intravenously (iv 1 mg/kg) and demonstrated limited oral exposure (AUC=2.6 μM·h , 5 mg/kg orally) [1].
|
References |
[1]. Jun Liang, et al. Lead Optimization of a 4-aminopyridine Benzamide Scaffold to Identify Potent, Selective, and Orally Bioavailable TYK2 Inhibitors. J Med Chem. 2013 Jun 13;56(11):4521-36.
|
Molecular Formula |
C16H13CL2N3O2
|
---|---|
Molecular Weight |
350.199
|
CAS # |
1258292-64-6
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
ClC1C=CC=C(C=1C(NC1C=CN=C(C=1)NC(C1CC1)=O)=O)Cl
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~62.5 mg/mL (~178.47 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.94 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.94 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.8555 mL | 14.2776 mL | 28.5551 mL | |
5 mM | 0.5711 mL | 2.8555 mL | 5.7110 mL | |
10 mM | 0.2856 mL | 1.4278 mL | 2.8555 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.